What medical device regulatory affairs does
Regulatory affairs (RA) is the function that turns regulations into a plan a company can execute. RA teams decide how a device will reach each market, prepare and defend submissions, keep registrations current and make sure changes, labeling and postmarket actions stay within the rules. In small device companies, which are the majority (more than 80% of US device firms have fewer than 50 employees, according to AdvaMed), RA is often one or two people who also cover quality.
For regulatory affairs across pharma and medical devices, and how eCTD 4.0, eSTAR and AI are changing it, see Regulatory Affairs in Life Sciences: What the Function Does and How It Is Changing.
Responsibilities across the device lifecycle
| Stage | RA responsibilities | Key outputs |
|---|---|---|
| Concept | Intended use, classification, regulatory strategy by market | Regulatory strategy, classification rationale |
| Development | Standards and guidance selection, pre-submission meetings, clinical strategy input | Pre-sub package, standards list, testing plan |
| Submission | Compile and submit 510(k), De Novo, PMA; EU technical documentation | eSTAR submission, technical file, responses to deficiency letters |
| Launch | Registration and listing, UDI/GUDID, EUDAMED, labeling and promotional review | Registrations, approved labeling and claims |
| Postmarket | Change assessments (new 510(k)?), MDR/vigilance reporting support, recalls, renewals | Change assessments, reports, renewals |
| Inspections and audits | Support FDA inspections and notified body audits; regulatory input to 483 responses | Inspection support, commitments tracking |
Where RA and QA meet
Under FDA’s Quality Management System Regulation (QMSR), effective February 2, 2026, the line between RA and QA is thinner. FDA’s inspection program, CP 7382.850, examines change control as one of six QMS areas (FDA), and change control is exactly where RA decides whether a change needs a new submission. Records such as management reviews and internal audits are now open to FDA inspection (FDA QMSR FAQ), so RA needs to know what they say.
Skills and careers in medical device regulatory affairs
Strong RA professionals combine four kinds of skill:
- Regulatory knowledge: 21 CFR, FDA guidance, EU MDR/IVDR, ISO 13485, ISO 14971, IEC 62304 and recognized standards.
- Scientific and technical literacy: enough engineering, clinical and software understanding to judge evidence.
- Writing and argument: submissions are persuasive technical documents; deficiency responses even more so.
- Project and stakeholder management: RA coordinates R&D, clinical, quality, marketing and external consultants.
Pay reflects the responsibility. RAPS’s 2022 compensation report put average total compensation for US-based regulatory professionals at $355,575 for vice presidents and $101,294 for associates (RAPS). The figures cover the whole healthcare products sector, not only devices, and are now several years old.
The Regulatory Affairs Certification (RAC) from RAPS is the most widely recognized professional credential, though many roles value direct submission experience more.
Six trends reshaping regulatory affairs in 2026
1. A thinner FDA
CDRH says it remains on track for its review timelines despite staff cuts, while guidance output fell from 38 documents to 21 in 2025 (MedTech Dive). By April 2026, FDA had lost about 21% of its staff, and companies reported less consistent reviewer feedback (MedTech Dive). In late 2025, CDRH director Michelle Tarver acknowledged the center was working with “fewer hands” (RAPS). For RA teams, that means fewer chances to fix weak submissions in review. Get it right the first time.
2. Digital submissions are now the default
eSTAR has been mandatory for 510(k)s since October 1, 2023 and for De Novo requests since October 1, 2025. Submissions go through the CDRH Portal, where, in FDA’s words, “Anyone can register” (FDA). Structured templates reduce refusals for missing content but make inconsistencies across sections easier to spot.
3. FDA reviewers use AI
FDA launched its agency-wide generative AI tool, Elsa, on June 2, 2025 (RAPS), and announced agentic AI capabilities for staff on December 1, 2025 (PharmTech). Expect faster cross-checking of claims, predicates and data across a submission. Inconsistent numbers, unsupported statements and outdated standard references are more likely to be found.
4. MDUFA VI and higher fees
FY2027 fees took effect October 1, 2026: $28,653 for a 510(k) and $636,732 for a PMA (Federal Register). The draft MDUFA VI commitment letter, published ahead of an August 5, 2026 public meeting, must be enacted by September 30, 2027 (RAPS). Exponent notes a proposed $2,000 fee for pre-submissions (Exponent), which would change how often companies use them.
5. EU data obligations
The first four EUDAMED modules became mandatory on May 28, 2026 (HPRA), with registration of devices, including legacy devices, due by November 28, 2026 (TÜV NORD). Meanwhile, a broader MDR and IVDR revision is targeted for adoption in mid-2027 (Emergo by UL).
6. AI inside RA teams, with trust issues
In RegASK’s 2024 report, a vendor survey, 39% of regulatory affairs respondents were using AI, but only 22% of those allowed to use ChatGPT for compliance guidance fully trusted its responses (RegASK via Business Wire). Veeva’s 2025 benchmark, also vendor-run, found that only 17% of medtech companies rate their regulatory data quality as excellent (Veeva). The lesson: AI helps RA when it works on good data and shows its sources.
Regulatory affairs operating model checklist
- Regulatory strategy documented for each product and market, reviewed at design reviews
- Regulatory intelligence process tracks FDA guidance, recognized standards, fees and EU changes
- Pre-submission strategy accounts for proposed MDUFA VI fees
- eSTAR submissions checked for internal consistency before filing
- Change control includes a documented regulatory impact assessment for every change
- Registrations, listings, GUDID and EUDAMED records reconciled at least annually
- Labeling and promotional claims reviewed against cleared or approved indications
- RA supports inspection readiness for the six QMS areas
- AI tools used by RA cite sources and are validated proportionate to risk
- Regulatory data owned, structured and kept in one system of record
Give your RA team evidence on demand
RA work is document work: checking that a technical file supports a claim, that a procedure meets a new requirement, that a change does not alter the basis of clearance. AI document assessment can read those documents against regulations and standards, flag gaps and cite the passage behind every finding, so RA professionals spend their time on judgment.
Run a sample regulatory document assessment on one submission section or technical file. AskDona shows the evidence; your RA team decides.
FAQ
What does a medical device regulatory affairs specialist do? Plans regulatory strategy, prepares submissions, maintains registrations and reviews labeling, changes and postmarket actions for compliance.
What is the difference between regulatory affairs and quality assurance? RA manages the relationship with regulators and market access; QA runs the quality management system. Under QMSR the two overlap heavily, especially in change control.
How much do regulatory affairs professionals earn? RAPS’s 2022 report found average total compensation of $101,294 for associates and $355,575 for vice presidents in the US (RAPS).
Is FDA using AI to review submissions? FDA staff use the agency’s generative AI tool, Elsa, launched in June 2025 (RAPS).
References
All pages opened and checked by October 13, 2026.
| Source | Type | Date | Used for |
|---|---|---|---|
| AdvaMed: Job creation | Trade association | 2021 data | Firm size |
| FDA: CP 7382.850 | Regulator | Feb 2, 2026 | Change control area |
| FDA: QMSR FAQ | Regulator | 2026 | Records open to FDA |
| RAPS: Average compensation | Professional body | Sep 13, 2022 | Salaries |
| MedTech Dive: CDRH on track | Trade press | Jan 29, 2026 | Guidance output |
| MedTech Dive: CDRH workloads | Trade press | Apr 1, 2026 | Staff loss, feedback |
| RAPS: Tarver on MDUFA metrics | Professional body | Oct 10, 2025 | ”Fewer hands” |
| FDA: CDRH Portal | Regulator | Current | eSTAR |
| RAPS: Elsa launch | Professional body | Jun 2025 | FDA AI |
| PharmTech: Agentic AI at FDA | Trade press | Dec 2025 | FDA agentic AI |
| Federal Register: FY2027 user fees | Regulator | 2026 | Fees |
| RAPS: MDUFA VI draft | Professional body | Jul 8, 2026 | MDUFA VI |
| Exponent: Draft MDUFA VI | Consultancy | Aug 14, 2026 | Pre-sub fee |
| HPRA: EUDAMED | Regulator (EU) | 2026 | EUDAMED |
| TÜV NORD: EUDAMED | Notified body | 2026 | Registration deadline |
| Emergo by UL: MDR/IVDR revision | Consultancy | Oct 9, 2026 | EU reform |
| RegASK via Business Wire | Vendor survey | Nov 14, 2024 | AI use |
| Veeva: MedTech benchmark | Vendor survey | 2025 | Data quality |